Figg WD - Search Results

1

Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.

Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N, Hamasaki M, Yasui H, Munshi NC, Richardson P, Figg WD, Anderson KC. Kumar S, et al. Among authors: figg wd. Leukemia. 2005 Jul;19(7):1253-61. doi: 10.1038/sj.leu.2403776. Leukemia. 2005. PMID: 15858615

2

Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma.

Barton BE, Collins MK, Chau CH, Choo-Wosoba H, Venzon DJ, Steinebach C, Garchitorena KM, Shah B, Sarin EL, Gütschow M, Figg WD. Barton BE, et al. Among authors: figg wd. Biomolecules. 2024 Jun 19;14(6):725. doi: 10.3390/biom14060725. Biomolecules. 2024. PMID: 38927128 Free PMC article.

3

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD. Dixon SC, et al. Among authors: figg wd. Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84. doi: 10.1007/s002800051103. Cancer Chemother Pharmacol. 1999. PMID: 10357564

4

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.

Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Fine HA, et al. Among authors: figg wd. J Clin Oncol. 2000 Feb;18(4):708-15. doi: 10.1200/JCO.2000.18.4.708. J Clin Oncol. 2000. PMID: 10673511 Clinical Trial.

5

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.

Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. Blagosklonny MV, et al. Among authors: figg wd. Leukemia. 2001 Oct;15(10):1537-43. doi: 10.1038/sj.leu.2402257. Leukemia. 2001. PMID: 11587211

6

Thalidomide, an antiangiogenic agent with clinical activity in cancer.

Ng SS, Brown M, Figg WD. Ng SS, et al. Among authors: figg wd. Biomed Pharmacother. 2002 Jun;56(4):194-9. doi: 10.1016/s0753-3322(02)00177-4. Biomed Pharmacother. 2002. PMID: 12109812 Review.

7

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.

Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Ng SS, et al. Among authors: figg wd. Cancer Res. 2003 Jun 15;63(12):3189-94. Cancer Res. 2003. PMID: 12810647

8

Thalidomide.

Franks ME, Macpherson GR, Figg WD. Franks ME, et al. Among authors: figg wd. Lancet. 2004 May 29;363(9423):1802-11. doi: 10.1016/S0140-6736(04)16308-3. Lancet. 2004. PMID: 15172781 Review.

9

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.

Ng SS, MacPherson GR, Gütschow M, Eger K, Figg WD. Ng SS, et al. Among authors: figg wd. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4192-7. doi: 10.1158/1078-0432.CCR-03-0700. Clin Cancer Res. 2004. PMID: 15217957

10

Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.

Warfel NA, Lepper ER, Zhang C, Figg WD, Dennis PA. Warfel NA, et al. Among authors: figg wd. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3502-9. doi: 10.1158/1078-0432.CCR-05-1837. Clin Cancer Res. 2006. PMID: 16740776

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters